erlotinib has been researched along with azd3759 in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (azd3759) | Trials (azd3759) | Recent Studies (post-2010) (azd3759) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 21 | 1 | 21 |
| Protein | Taxonomy | erlotinib (IC50) | azd3759 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0192 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0033 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.622 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.797 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0033 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.156 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0033 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, K; Cheng, Z; Johnström, P; Li, DY; Varnäs, K; Wang, J; Yang, ZF; Zeng, Q; Zhang, X | 1 |
1 other study(ies) available for erlotinib and azd3759
| Article | Year |
|---|---|
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Topics: Animals; Brain; Brain Neoplasms; Central Nervous System; Clinical Trials, Phase I as Topic; Dogs; Drug Discovery; ErbB Receptors; Macaca fascicularis; Male; Mice; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2015 |